期刊文献+

UGT1A1基因多态性与伊立替康治疗结直肠癌不良反应的关系 被引量:11

Relationship between UGT1A1 gene polymorphisms and toxicity of irinotecan-based chemotherapy in colorectal cancer
下载PDF
导出
摘要 背景与目的:尿苷二磷酸葡萄糖醛酸转移酶1A1(uridine diphosphoglucu-ronosyl transferase 1A1,UGTlA1)是伊立替康代谢关键酶,其活性受基因多态性影响显著。本研究探讨结直肠癌患者中,UGT1A1*28和UGT1A1*6基因多态性与伊立替康治疗相关不良反应之间的关系。方法:入组2013年4月—2013年12月于复旦大学附属中山医院肿瘤内科接受治疗的消化道恶性肿瘤患者160例。抽提外周血中基因组DNA,分别采用STR方法和Sanger测序法,检测UGT1A1*28和UGT1A1*6基因型,分析UGT1A1基因多态性分布情况。对其中82例化疗方案中含伊立替康的结直肠癌患者进行随访,记录不良反应发生情况和严重程度,比较不同基因型患者之间的差异。结果:160例消化道肿瘤患者中,UTG1A1*28(启动子TATA盒区域TA重复次数)野生型TA6/6124例(77.5%);杂合子TA6/7 33例(20.5%);纯合子TA7/7 3例(2.0%)。UGT1A1*6位点(211G>A)野生型GG 105例(65.6%),杂合子GA 48例(30.0%);纯合子AA 7例(4.4%)。82例化疗方案中含伊立替康的结直肠癌患者中,*28基因型(TA6/7和TA7/7)显著增加发生3级以上中性粒细胞减少的风险(58.3%vs 0.0%,P<0.001),并增加整体不良反应发生率(76.0%vs 45.6%,P<0.001);*6基因型(GA和AA)、年龄、性别、化疗方案和伊立替康相关不良反应发生无显著相关性。结论:接受伊立替康化疗的结直肠癌患者,UGT1A1*28位点多态性显著增加中性粒细胞减少发生的风险,可预测伊立替康引起的骨髓抑制性不良反应,辅助临床选择合适的化疗方案。 Background and purpose: Uridine diphosphoglucu-ronosyl transferase 1A1 (UGT1A1) is an important enzyme for metabolism of irinotecan. The activity of UGT1A1 enzyme was significantly affected by the gene polymorphism. This study aimed to investigate the correlation of UGT1A1*28 and *6 gene polymorphisms with irinotecan-based chemotherapy in colorectal cancer(CRC). Methods: Analysis of UGT1A1*28 and *6 gene polymorphisms was performed in 160 gastrointestinal cancer patients admitted to Zhongshan Hospital Fudan University from Apr. 2013 to Dec. 2013 by amplifying the gene fragments using PCR, STR and Sanger sequencing. Eighty-two cases with CRC treated with irinotecan were chosen to observe the adverse events during chemotherapy. The incidence of different genotypes was compared. Results:The distribution of the genotypes in 160 gastrointestinal cancer patients was as followed:UGT1A1*28 wild-type genotype TA6/6 (124, 77.5%), heterozygous genotype TA6/7 (33, 20.5%), and homozygous genotype TA7/7 (3, 2.0%);UGT1A1*6 wild-type genotype GG (105, 65.6%), heterozygous genotype GA (48, 30.0%), and homozygous genotype AA (7, 4.4%). In the 82 CRC cases, the incidences of grade 3 and 4 neutropenia in the patients carrying UGT1A1*28 (TA6/7+TA7/7 ) were higher than those in the WT genotype (TA6/6) (58.3%vs 0.0, P〈0.001), and increased the total incidence of adverse events (76.0%vs 45.6%, P〈0.001). There was no signiifcant relevance between UGT1A1*6 genotype, age, gender chemotherapy and adverse events. Conclusion:In the CRC cases with irinotecan-based chemotherapy, the UGT1A1*28 (TA6/7+TA7/7) genotype signiifcantly increased the risk of grade 3 and 4 neutropenia. Detecting UGT1A1 gene polymorphisms may guide individualized treatment and predict adverse events.
出处 《中国癌症杂志》 CAS CSCD 北大核心 2014年第7期493-500,共8页 China Oncology
基金 国家临床重点检验专科建设项目资助 "十二五"国家科技支撑计划子课题"中国人群常用临床检验项目参考区间及相关技术支撑体系的建立"资助(No:2012BAI37B01)
关键词 伊立替康 UGT1A1 基因多态性 不良反应 结直肠癌 Irinotecan UGT1A1 Gene polymorphisms Adverse events Colorectal cancer
  • 相关文献

参考文献4

二级参考文献67

  • 1张新玉,田辉.遗传性非结合型高胆红素血症[J].肝脏,2005,10(1):51-52. 被引量:5
  • 2Garcia-Carbonero R,Supko JG.Current perspectives on the clinical experience,pharmacology,and continued development of the camptothecins.Clin Cancer Res 2002; 8:641-661.
  • 3Ulukan H,Swaan PW.Camptothecins:a review of their chemotherapeutic potential.Drugs 2002; 62:2039-2057.
  • 4Saltz LB,Cox JV,Blanke C,Rosen LS,Fehrenbacher L,Moore MJ,Maroun JA,Ackland SP,Locker PK,Pirotta N,Elfring GL,Miller LL.Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.Irinotecan Study Group.N Engl J Med 2000; 343:905-914.
  • 5Folprecht G,Kohne CH.The role of new agents in the treatment of colorectal cancer.Oncology 2004; 66:1-17.
  • 6Kawato Y,Aonuma M,Hirota Y,Kuga H,Sato K.Intracellular roles of SN-38,a metabolite of the camptothecin derivative CPT-11,in the antitumor effect of CPT-11.Cancer Res 1991; 51:4187-4191.
  • 7Vanhoefer U,Harstrick A,Achterrath W,Cao S,Seeber S,Rustum YM.Irinotecan in the treatment of colorectal cancer:clinical overview.J Clin Oncol 2001; 19:1501-1518.
  • 8Araki E,Ishikawa M,Iigo M,Koide T,Itabashi M,Hoshi A.Relationship between development of diarrhea and the concentration of SN-38,an active metabolite of CPT-11,in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11.Jpn J Cancer Res 1993; 84:697-702.
  • 9Gupta E,Lestingi TM,Mick R,Ramirez J,Vokes EE,Ratain MJ.Metabolic fate of irinotecan in humans:correlation of glucuronidation with diarrhea.Cancer Res 1994; 54:3723-3725.
  • 10Bosma PJ.Inherited disorders of bilirubin metabolism.J Hepatol 2003; 38:107-117.

共引文献84

同被引文献123

引证文献11

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部